By ED SILVERMAN
Source - WSJ
The tussle over the cost of the Sovaldi hepatitis C medication may prevent yet another segment of the population from being treated – people who are enrolled in opioid treatment programs.
Although the drug has shown evidence of curing nine of 10 sufferers and theproduct labeling does not suggest Sovaldi is not safe for these patients, payers are balking at covering the medicine for people with a history of a substance use disorder, according to Alcoholism & Drug Abuse Weekly.
Continue To Article...
No comments:
Post a Comment